Congress·In Committee·S. 3751
Prescription Drug Supply Chain Pricing Transparency Act
Prescription Drug Pricing: Study on Supply Chain Fees
Legislative Progress
Senate
Key Points
- Senators Bennet and Lankford introduced a bill to investigate how "middleman" companies in the drug industry make their money and how that affects what you pay at the pharmacy.
- The study will look at whether companies that manage drug benefits and insurance providers are getting paid fees based on a percentage of a drug's high price.
- Investigators will look for conflicts of interest, such as whether these companies choose expensive drugs over cheaper ones just to collect higher fees.
- The goal is to uncover hidden deals that might be making medicine more expensive for people using government programs like Medicare and Medicaid.
- The government watchdog must finish this study and give Congress a list of ways to fix these pricing problems within two years.
Impact Analysis
Govbase has not yet run an impact analysis on this legislation.
Milestones
2 milestones2 actions
Jan 29, 2026
Read twice and referred to the Committee on Finance.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Jan 29, 2026
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
Prescription Drug Supply Chain Pricing Transparency Act
Bill NumberS 3751
Congress119th Congress
ChamberSenate
Latest ActionRead twice and referred to the Committee on Finance.
Data Sources
Sponsor
Cosponsors
(1)R: 1
Analysis generated by AI. Always verify with official sources.